Our Press Releases | Association for Accessible Medicines

Access! 2023 + IGBA 2023 Conference - Last chance to register, join us in Orlando, FL on Feb 13-16!

Ariel with Medicines

May 23, 2022 | Allen Goldberg

AAM Statement in Response to Federal Trade Commission Request for Information on PBM Business Practices

May 16, 2022 | Allen Goldberg

Association for Accessible Medicines Names Craig Burton as Senior Vice President, Policy & Strategic Alliances, and Executive Director of the Biosimilars Council

Headquarter of the U.S. Food and Drug Administration (FDA)

May 11, 2022 | Allen Goldberg

AAM Statement on House Energy and Commerce Health Subcommittee Markup of H.R. 7667 Reauthorizing Generic Drug and Biosimilar User Fee Amendments

Apr 1, 2022 | Rachel Schwartz

HHS Finds Biosimilars Use Results in “Significant Spending Reduction” For Medicare and Its Beneficiaries

Dr. Robert Califf

Feb 15, 2022 | Rachel Schwartz

AAM Statement on the Confirmation of Robert Califf to Lead FDA

Academy of Managed Care Pharmacy (AMCP)

Feb 15, 2022 | Rachel Schwartz

Academy of Managed Care Pharmacy Named AAM’s 2022 Champion of Access

AAM board room

Feb 14, 2022 | Rachel Schwartz

Chirag Patel Named Chair of the Association for Accessible Medicines Board of Directors

AAM board room

Feb 14, 2022 | Rachel Schwartz

AAM Announces 2022 Board of Directors

AAM Lobby

Feb 14, 2022 | Rachel Schwartz

AAM Announces 2022 Associate Members

Team of inspectors

Feb 2, 2022 | Rachel Schwartz

AAM Statement on FDA User Fee Reauthorization

AAM Statement on Avalere Report

Jan 24, 2022 | Rachel Schwartz

Avalere Analysis Finds Medicare Part D Patients Continue to Pay More for Generics

Doesn't Add Up patient photo

Nov 19, 2021 | Rachel Schwartz

Association for Accessible Medicines Warns Build Back Better Act Threatens Patient Access